A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

BACKGROUND: This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors. OBJECTIV...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Target Oncol
Hlavní autoři: Wainberg, Zev A., Alsina, Maria, Soares, Heloisa P., Braña, Irene, Britten, Carolyn D., Del Conte, Gianluca, Ezeh, Patrick, Houk, Brett, Kern, Kenneth A., Leong, Stephen, Pathan, Nuzhat, Pierce, Kristen J., Siu, Lillian L., Vermette, Jennifer, Tabernero, Josep
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2017
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5700209/
https://ncbi.nlm.nih.gov/pubmed/29067643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-017-0530-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky